Spots Global Cancer Trial Database for chronic phase chronic myeloid leukemia

Every month we try and update this database with for chronic phase chronic myeloid leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib	NCT01593254	Chronic Phase C...	Imatinib Dasatinib	18 Years -	Bristol-Myers Squibb
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States	NCT03045120	Chronic Phase C...		18 Years -	Bristol-Myers Squibb
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses	NCT02467270	Myeloid Leukemi...	Ponatinib	18 Years -	Takeda
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response	NCT01850004	Chronic Phase C...	Dasatinib	18 Years -	Bristol-Myers Squibb
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States	NCT03045120	Chronic Phase C...		18 Years -	Bristol-Myers Squibb
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib	NCT01660906	Chronic Phase C...	Dasatinib	18 Years -	Bristol-Myers Squibb
Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene	NCT02885766	Chronic Myeloid... Leukemia, Myelo...	PF-114	18 Years -	Fusion Pharma LLC
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors	NCT03610971	Chronic Phase C... Chronic Myeloid...	Ruxolitinib BCR-ABL Tyrosin...	18 Years -	H. Lee Moffitt Cancer Center and Research Institute
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors	NCT03934372	Acute Myeloid L... Accelerated Pha... Blast Phase Chr... Chronic Phase C... Acute Lymphobla... Acute Lymphocyt... Leukemia Lymphoma Solid Tumors	Ponatinib	1 Year - 17 Years	Incyte Corporation
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response	NCT01850004	Chronic Phase C...	Dasatinib	18 Years -	Bristol-Myers Squibb
A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia	NCT02627677	Chronic Phase C...	Ponatinib 30 mg... Ponatinib 15 mg... Nilotinib 400 m...	18 Years -	Takeda
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia	NCT01914484	Chronic Phase C... Accelerated Pha... Blastic Phase C... Philadelphia Po... Resistant to Ty...	Nilotinib Ruxolitinib	18 Years -	University Health Network, Toronto
Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response	NCT01933906	Chronic Phase C...	P1101	18 Years -	Arbeitsgemeinschaft medikamentoese Tumortherapie
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response	NCT01850004	Chronic Phase C...	Dasatinib	18 Years -	Bristol-Myers Squibb
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response	NCT01850004	Chronic Phase C...	Dasatinib	18 Years -	Bristol-Myers Squibb
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib	NCT01593254	Chronic Phase C...	Imatinib Dasatinib	18 Years -	Bristol-Myers Squibb

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: